SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-21-031671
Filing Date
2021-06-04
Accepted
2021-06-04 07:05:27
Documents
12
Period of Report
2021-05-28
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ortx-8k_20210528.htm   iXBRL 8-K 43082
  Complete submission text file 0001564590-21-031671.txt   169442

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ortx-20210528.xsd EX-101.SCH 5784
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ortx-20210528_lab.xml EX-101.LAB 18644
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ortx-20210528_pre.xml EX-101.PRE 11159
5 EXTRACTED XBRL INSTANCE DOCUMENT ortx-8k_20210528_htm.xml XML 3473
Mailing Address 108 CANNON STREET LONDON X0 EC4N 6EU
Business Address 108 CANNON STREET LONDON X0 EC4N 6EU 011-44-0-203-3846700
Orchard Therapeutics plc (Filer) CIK: 0001748907 (see all company filings)

IRS No.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38722 | Film No.: 21994844
SIC: 2836 Biological Products, (No Diagnostic Substances)